刊物

Pharmacokinetics of L-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension.

Find out how short 16‑min half‑life; simulations support 37–52 mg/kg QID dosing using Phoenix WinNonlin.

Certara2022 年 10 月 31 日

Publication

Population Pharmacokinetic Analysis of Valsartan in Healthy Chinese Subjects

Explore how food affects absorption; liver enzymes and creatinine influence clearance in valsartan PopPK using…

Certara2022 年 10 月 26 日

Publication

Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach

Discover how species differences in PK and metabolite ratios explain efficacy variation using Phoenix WinNonlin.

Certara2022 年 9 月 11 日

Publication

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

See how early clearance drop predicts better response and survival; PopPK built using Phoenix NLME.

Certara2022 年 9 月 6 日

Publication

Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients

Learn how creatinine clearance and ALT drive PK; simulations show need for adjusted dosing using…

Certara2022 年 8 月 29 日

刊物

Pharmacokinetic Study of Nalbuphine in Surgical Patients Undergoing General Anesthesia with Varying Degrees of Liver Dysfunction.

Find out how Liver dysfunction increases nalbuphine half‑life and Vd; PK analysed using Phoenix WinNonlin.

Certara2022 年 7 月 26 日

Publication

Leveraging a Previously Published Population Pharmacokinetic Model to Predict Rivaroxaban Exposure in Real-World Patients

Explore how model predicts population‑level target attainment but large individual variability using Phoenix NLME.

Certara2022 年 7 月 25 日

刊物

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.

Discover how itraconazole markedly increases SHR2554 exposure; PK interaction assessed using Phoenix WinNonlin.

Certara2022 年 7 月 16 日

Conference

2026 ACCP Annual Meeting

–

Certara2022 年 7 月 15 日

刊物

CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response.

See how CYP2A6 affects exposure; GABRA2 predicts heart‑rate abnormalities using Phoenix NLME.

Certara2022 年 7 月 7 日

沪ICP备2022021526号

Powered by Translations.com GlobalLink Web Software

建模与模拟

Pharmacokinetics of L-Citrulline in Neonates at Risk of Developing Bronchopulmonary Dysplasia-Associated Pulmonary Hypertension.

Population Pharmacokinetic Analysis of Valsartan in Healthy Chinese Subjects

Evaluating the efficacy of prototype antiseizure drugs using a preclinical pharmacokinetic approach

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Population pharmacokinetics of intravenous colistin sulfate and dosage optimization in critically ill patients

Pharmacokinetic Study of Nalbuphine in Surgical Patients Undergoing General Anesthesia with Varying Degrees of Liver Dysfunction.

Leveraging a Previously Published Population Pharmacokinetic Model to Predict Rivaroxaban Exposure in Real-World Patients

Study on pharmacokinetic interactions between SHR2554 and itraconazole in healthy subjects: A single-center, open-label phase I trial.

2026 ACCP Annual Meeting

CYP2A6 and GABRA2 Gene Polymorphisms are Associated With Dexmedetomidine Drug Response.

订阅时事通讯

快捷链接

解决方案

联系我们